| MRSA acquisition in LTCFs (n = 65) | MRSA acquisition in hospitals (n = 21) | p value |
---|---|---|---|
Age (mean ± SD) | 85.1 ± 10.2 | 84.2 ± 10.8 | 0.744 |
Sex (male) | 24 (36.9%) | 8 (38.1%) | 0.923 |
Underlying diseases | Â | Â | Â |
  Chronic cerebral conditions a | 29 (44.6%) | 7 (33.3%) | 0.362 |
  Chronic cardiac conditions b | 8 (12.3%) | 6 (28.6%) | 0.079 |
  Chronic pulmonary conditions c | 7 (10.8%) | 3 (14.3%) | 0.662 |
  Chronic renal failure | 2 (3.1%) | 2 (9.5%) | 0.223 |
  Liver cirrhosis | 0 | 0 | NA |
  Diabetes mellitus | 11 (16.9%) | 5 (23.8%) | 0.481 |
  Malignancy | 4 (6.2%) | 1 (4.8%) | 0.813 |
Presence of | Â | Â | Â |
  Nasogastric tube | 23 (35.4%) | 7 (33.3%) | 0.864 |
  Urinary catheter | 15 (23.1%) | 3 (14.3%) | 0.389 |
  Tenckhoff catheter | 0 | 0 | NA |
  Wound or ulcer | 1 (1.5%) | 2 (9.5%) | 0.083 |
Antibiotics therapy within 3 months of MRSA screening | Â | Â | Â |
  Penicillin group | 11 (16.9%) | 6 (28.6%) | 0.244 |
  β-lactam/β-lactamase inhibitors | 23 (35.4%) | 8 (38.1%) | 0.822 |
  Cephalosporin group | 7 (10.8%) | 3 (14.3%) | 0.662 |
  Carbapenem group | 0 | 1 (4.8%) | 0.077 |
  Fluoroquinolones | 2 (3.1%) | 2 (9.5%) | 0.223 |